Drug Profile
Research programme: viral infection therapeutics - Phoenix Biotechnology
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Phoenix Biotechnology
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections; HIV infections; Respiratory syncytial virus infections; Viral haemorrhagic fevers
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cytomegalovirus infections in USA (unspecified route)
- 31 Aug 2023 Discontinued - Preclinical for HIV infections in USA (unspecified route)
- 31 Aug 2023 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)